HCPLive Network

Metformin Cuts Cardiovascular Events in High-Risk Patients with Type 2 Diabetes

MONDAY, Jan. 7 (HealthDay News) -- Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.

Jie Hong, M.D., from the Shanghai Jiao Tong University School of Medicine, and colleagues conducted a multicenter trial in which 304 patients with type 2 diabetes with coronary artery disease (mean age, 63.3 years) were randomized to receive glipizide (30 mg daily) or metformin (1.5 g daily) for three years. The composite end point was times to recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revascularization.

The researchers found that both groups achieved a significant reduction in the level of glycated hemoglobin (7.1 percent in the glipizide group and 7.0 percent in the metformin group). Ninety-one participants developed 103 primary end points over a median follow-up of five years. The adjusted hazard ratio for the composites of cardiovascular events among the patients that received metformin versus glipizide was 0.54. There was no significant difference between the two groups for secondary end points and adverse events.

"Treatment with metformin for three years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide," the authors write.

The glipizide and metformin were provided by the Xinyi Pharmaceutical Co.

Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
In addition to traditional cardiovascular disease risk factors, in patients with type 2 diabetes, coronary artery calcium predicts the risk of cardiovascular death, according to a study published online Dec. 10 in Diabetes Care.
There is an association between higher diet drink intake and cardiovascular disease and mortality in postmenopausal women, according to a study presented at the annual meeting of the American College of Cardiology, held from March 29 to 31 in Washington, DC.
Landmark study results presented at ACC.13 reveal patients with vascular disease treated with niacin therapy face increased risk of myopathy and other adverse events.
For patients with type 2 diabetes, treatment with the dipeptidyl peptidase 4 inhibitors saxagliptin or alogliptin is not associated with improvements in cardiovascular risk, according to two studies published online Sept. 2 in the New England Journal of Medicine to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 31 to Sept. 4 in Amsterdam.
Men and women with fatty liver are more likely to have metabolic syndrome with type 2 diabetes, and women with fatty liver are more likely to have metabolic syndrome with subclinical atherosclerosis, according to research published online Dec. 18 in Diabetes Care.
Lowering blood pressure below 130 mm Hg does not improve cardiovascular outcomes in patients with hypertension, diabetes, and coronary artery disease.
The AleCardio trial was halted early due to safety concerns and lack of efficacy. Investigators reported patients with diabetes and acute coronary syndrome experienced elevated risk of heart failure, gastrointestinal hemorrhage, and renal dysfunction with no mitigating cardiovascular benefit.
More Reading